文献速递心脏核医学

靶向稳定蛋白2的18F-S2P PET显像用于临床前模型动脉粥样硬化斑块成像

PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracer 18F-S2P in preclinical models.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-04

本研究在Ldlr-/-小鼠模型中验证了靶向稳定蛋白2(STAB2)的18F-S2P PET示踪剂识别动脉粥样硬化斑块的可行性,并与18F-FDG和18F-Pentixafor比较。结果显示18F-S2P斑块摄取随病程增加且与组织学斑块负荷正相关,在Ldlr-/-小鼠中斑块摄取较野生型对照高5.4倍(P<0.0001),优于18F-FDG(1.52倍)和18F-Pentixafor(1.89倍),人动脉粥样硬化标本中也可检测到STAB2表达。

要点

  • 18F-S2P在Ldlr-/-小鼠斑块摄取随病程增加(12周vs 3周:2.17±0.19 vs 1.41±0.31 ID%/g,P<0.0001)。
  • 18F-S2P斑块摄取较野生型对照高5.4倍(P<0.0001),优于18F-FDG和18F-Pentixafor。
  • 人动脉粥样硬化斑块中可检测到STAB2表达,支持转化潜力。

核心结论

  • 18F-S2P是一种靶向STAB2的新型PET探针,可在临床前模型中无创成像动脉粥样硬化斑块并检测炎症。
  • STAB2在人动脉粥样硬化病变中的内源性表达增强了该成像策略的转化潜力。

研究设计与样本

  • 通过Ldlr-/-小鼠样本的单细胞RNA测序验证Stab2表达。
  • 在高脂饮食喂养的Ldlr-/-小鼠(3-12周)和普通饲料对照中进行生物分布和micro-PET/CT成像,并与18F-FDG和18F-Pentixafor比较。
  • 使用油红O、H&E和免疫荧光染色评估斑块负荷和巨噬细胞浸润,免疫组化检测人动脉粥样硬化标本中STAB2表达。

主要发现

  • 单细胞RNA测序分析确定Stab2为动脉粥样硬化斑块中的巨噬细胞特异性标志物。
  • 体内micro-PET/CT定量显示18F-S2P摄取随病程增加(3周1.41±0.31 ID%/g vs 12周2.17±0.19 ID%/g,P<0.0001),与组织学斑块负荷正相关。
  • 18F-S2P PET在Ldlr-/-小鼠斑块摄取较野生型对照高5.4倍(P<0.0001),在动脉粥样硬化病变中显著优于18F-FDG(1.52倍)和18F-Pentixafor(1.89倍)。
  • 人动脉粥样硬化斑块中可检测到STAB2表达。

临床怎么用

  • 18F-S2P PET有望作为无创检测动脉粥样硬化炎症的分子成像工具,用于临床前研究和未来转化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Elevated Stabilin-2 (STAB2) expression in macrophages within atherosclerotic plaques offers a promising molecular target for imaging vascular inflammation. The S2P peptide specifically binds STAB2. This study aims to evaluate the feasibility of using the STAB2-targeted 18F-labeled tracer (18F-S2P) for positron emission tomography (PET) imaging to identify atherosclerotic plaques. METHODS: Stab2 expression was validated via single-cell RNA sequencing of Ldlr-/- mouse samples. Biodistribution and micro-PET/CT imaging were performed in high-fat diet-fed Ldlr-/- mice (3-12 weeks) and chow-fed controls, with comparisons to 18F-FDG and 18F-Pentixafor. Plaque burden and macrophage infiltration were evaluated using Oil Red O, H&E, and immunofluorescence staining. Immunohistochemical staining was used to detect STAB2 expression in human atherosclerotic specimens. RESULTS: ScRNA-seq analysis identified Stab2 as a macrophage-specific marker in atherosclerosis plaque. In vivo micro-PET/CT quantification revealed disease duration-dependent uptake (1.41 ± 0.31 ID%/g at 3 weeks vs. 2.17 ± 0.19 ID%/g at 12 weeks, P < 0.0001), which positively correlated with histological plaque burden. 18F-S2P PET imaging demonstrated 5.4-fold higher plaque uptake in Ldlr-/- mice compared to wild-type controls (P < 0.0001), significantly outperforming 18F-FDG (1.52-fold) and 18F-Pentixafor (1.89-fold) in atherosclerotic lesions. Furthermore, STAB2 was also detectable in human atherosclerotic plaques. CONCLUSION: This study introduces a novel STAB2-targeted PET probe (18F-S2P) for non-invasive imaging of atherosclerotic plaques in preclinical models, enabling the detection of atherosclerotic inflammation. The endogenous expression of STAB2 in human atherosclerotic lesions further strengthens the translational potential of this imaging strategy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Adili D, Zhang D, Wang G, et al. PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracer 18F-S2P in preclinical models. Eur J Nucl Med Mol Imaging. 2026. PMID: 42400626. doi:10.1007/s00259-026-08033-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。